Data $11.49 | CCXI Message Board Posts


ChemoCentryx, Inc.

  CCXI website

CCXI   /  Message Board  /  Read Message

 

 






Keyword
Subject
Between
and
Rec'd By
Authored By
Minimum Recs
  
Previous Message  Next Message    Post Message    Post a Reply return to message boardtop of board
Msg  2 of 6  at  10/2/2012 1:17:04 PM  by

mlkrborn


Data $11.49

ChemoCentryx reports data for CCX872, the company's orally bioavailable, next-generation CCR2 inhibitor, in a preclinical model of diabetic nephropathy (CCXI) 11.89 : The findings showed that treatment with CCX872 improved multiple parameters of renal function in an in vivo model of diabetic nephropathy. The data were reported in an oral presentation titled, "CCR2 Inhibition Improves Renal Function in Diabetic BTBR ob/ob Mice," at the 48th Annual Meeting of the European Association for the Study of Diabetes taking place in Berlin. CX140 has successfully completed a Phase II clinical trial in type 2 diabetics as a gateway study to initiate clinical testing in patients with diabetic nephropathy. CCX140 is being evaluated in two ongoing Phase II studies in the latter patient population, with data expected to report in 2013.


     e-mail to a friend      printer-friendly     add to library      
|  
Recs: 0  
   Views: 643 []
Previous Message  Next Message    Post Message    Post a Reply return to message boardtop of board




Financial Market Data provided by
.
Loading...